A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee

Abstract Background: A promising novel cell‑free bioactive formulation for articular cartilage regeneration, called BIOF2, has recently been tested in pre‑clinical trials. The aim of the present study was to evaluate the efficacy and safety of BIOF2 for intra‑articular application in patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado Enciso, Iván, Paz Garcia, Juan, Valtierra Alvarez, Jose, Preciado Ramirez, Jorge, Almeida Trinidad, Román, Guzman Esquivel, José, Mendoza Hernandez, Martha A., García vega, Alberto, Soriano Hernandez, Alejandro D., Cortes Bazan, José L., Galvan Salazar, Héctor R., Cabrera Lincona, Ariana, Rodríguez Sánchez, Irám Pablo, Martínez Fierro, Margarita de la Luz, Delgado Enciso, Josuel, Paz Michel, Brenda
Formato: Artículo
Lenguaje:inglés
Publicado: 2018
Materias:
Acceso en línea:http://eprints.uanl.mx/15983/1/56.pdf
_version_ 1836397358714191872
author Delgado Enciso, Iván
Paz Garcia, Juan
Valtierra Alvarez, Jose
Preciado Ramirez, Jorge
Almeida Trinidad, Román
Guzman Esquivel, José
Mendoza Hernandez, Martha A.
García vega, Alberto
Soriano Hernandez, Alejandro D.
Cortes Bazan, José L.
Galvan Salazar, Héctor R.
Cabrera Lincona, Ariana
Rodríguez Sánchez, Irám Pablo
Martínez Fierro, Margarita de la Luz
Delgado Enciso, Josuel
Paz Michel, Brenda
author_facet Delgado Enciso, Iván
Paz Garcia, Juan
Valtierra Alvarez, Jose
Preciado Ramirez, Jorge
Almeida Trinidad, Román
Guzman Esquivel, José
Mendoza Hernandez, Martha A.
García vega, Alberto
Soriano Hernandez, Alejandro D.
Cortes Bazan, José L.
Galvan Salazar, Héctor R.
Cabrera Lincona, Ariana
Rodríguez Sánchez, Irám Pablo
Martínez Fierro, Margarita de la Luz
Delgado Enciso, Josuel
Paz Michel, Brenda
author_sort Delgado Enciso, Iván
collection Repositorio Institucional
description Abstract Background: A promising novel cell‑free bioactive formulation for articular cartilage regeneration, called BIOF2, has recently been tested in pre‑clinical trials. The aim of the present study was to evaluate the efficacy and safety of BIOF2 for intra‑articular application in patients with severe osteoarthritis of the knee. Methods: A prospective, randomized, 3‑arm, parallel group clinical trial was conducted. It included 24 patients with severe osteoarthritis of the knee (WOMAC score 65.9 ± 17). Before they entered the study, all the patients were under osteoarthritis control through the standard treatment with nonsteroidal anti‑inflammatory drugs (NSAIDs), prescribed by their family physician. Patients were distributed into three groups of 8 patients each (intra‑articular BIOF2, total joint arthroplasty, or conservative treatment with NSAIDs alone). The WOMAC score, RAPID3 score, and Rasmussen clinical score were evaluated before treatment and at months 3, 6, and 12. BIOF2 was applied at months 0, 3, and 6. Complete blood count and blood chemistry parameters were determined in the BIOF2 group before treatment, at 72 h, and at months 1, 3, 6, and 12. In addition, articular cartilage volume was evaluated (according to MRI) at the beginning of the study and at month 12. Results: The NSAID group showed no improvement at follow‑up. Arthroplasty and BIOF2 treatments showed significant improvement in all the scoring scales starting at month 3. There were no statistically significant differ‑ ences between the BIOF2 group and the arthroplasty group at month 6 (WOMAC score: 19.3 ± 18 vs 4.3 ± 5; P = 0.24) or month 12 (WOMAC score: 15.6 ± 15 vs 15.7 ± 17; P = 1.0). Arthroplasty and BIOF2 were successful at month 12 (according to a WOMAC score: ≤ 16) in 75% of the patients and the daily use of NSAIDs was reduced, compared with the group treated exclusively with NSAIDs (RR = 0.33, 95% CI 0.12–0.87, P = 0.02. This result was the same for BIOF2 vs NSAIDs and arthroplasty vs NSAIDs). BIOF2 significantly increased the articular cartilage by 22% (26.1 ± 10 vs 31.9 ± 10 cm2, P < 0.001) and produced a significant reduction in serum lipids. BIOF2 was well tolerated, causing slight‑to‑mod‑ erate pain only upon application. Conclusions: The intra‑articular application of the new bioactive cell‑free formulation (BIOF2) was well tolerated and showed no significative differences with arthroplasty for the treatment of severe osteoarthritis of the knee. BIOF2 can regenerate articular cartilage and is an easily implemented alternative therapy for the treatment of osteoarthritis. Trial registration Cuban Public Registry of Clinical Trials (RPCEC) Database RPCEC00000250. Registered 08/15/2017— Retrospectively registered, http://rpcec .sld.cu/en/trial s/RPCEC 00000 250‑En.
format Article
id eprints-15983
institution UANL
language English
publishDate 2018
record_format eprints
spelling eprints-159832025-06-26T18:00:12Z http://eprints.uanl.mx/15983/ A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee Delgado Enciso, Iván Paz Garcia, Juan Valtierra Alvarez, Jose Preciado Ramirez, Jorge Almeida Trinidad, Román Guzman Esquivel, José Mendoza Hernandez, Martha A. García vega, Alberto Soriano Hernandez, Alejandro D. Cortes Bazan, José L. Galvan Salazar, Héctor R. Cabrera Lincona, Ariana Rodríguez Sánchez, Irám Pablo Martínez Fierro, Margarita de la Luz Delgado Enciso, Josuel Paz Michel, Brenda QR Microbiología Abstract Background: A promising novel cell‑free bioactive formulation for articular cartilage regeneration, called BIOF2, has recently been tested in pre‑clinical trials. The aim of the present study was to evaluate the efficacy and safety of BIOF2 for intra‑articular application in patients with severe osteoarthritis of the knee. Methods: A prospective, randomized, 3‑arm, parallel group clinical trial was conducted. It included 24 patients with severe osteoarthritis of the knee (WOMAC score 65.9 ± 17). Before they entered the study, all the patients were under osteoarthritis control through the standard treatment with nonsteroidal anti‑inflammatory drugs (NSAIDs), prescribed by their family physician. Patients were distributed into three groups of 8 patients each (intra‑articular BIOF2, total joint arthroplasty, or conservative treatment with NSAIDs alone). The WOMAC score, RAPID3 score, and Rasmussen clinical score were evaluated before treatment and at months 3, 6, and 12. BIOF2 was applied at months 0, 3, and 6. Complete blood count and blood chemistry parameters were determined in the BIOF2 group before treatment, at 72 h, and at months 1, 3, 6, and 12. In addition, articular cartilage volume was evaluated (according to MRI) at the beginning of the study and at month 12. Results: The NSAID group showed no improvement at follow‑up. Arthroplasty and BIOF2 treatments showed significant improvement in all the scoring scales starting at month 3. There were no statistically significant differ‑ ences between the BIOF2 group and the arthroplasty group at month 6 (WOMAC score: 19.3 ± 18 vs 4.3 ± 5; P = 0.24) or month 12 (WOMAC score: 15.6 ± 15 vs 15.7 ± 17; P = 1.0). Arthroplasty and BIOF2 were successful at month 12 (according to a WOMAC score: ≤ 16) in 75% of the patients and the daily use of NSAIDs was reduced, compared with the group treated exclusively with NSAIDs (RR = 0.33, 95% CI 0.12–0.87, P = 0.02. This result was the same for BIOF2 vs NSAIDs and arthroplasty vs NSAIDs). BIOF2 significantly increased the articular cartilage by 22% (26.1 ± 10 vs 31.9 ± 10 cm2, P < 0.001) and produced a significant reduction in serum lipids. BIOF2 was well tolerated, causing slight‑to‑mod‑ erate pain only upon application. Conclusions: The intra‑articular application of the new bioactive cell‑free formulation (BIOF2) was well tolerated and showed no significative differences with arthroplasty for the treatment of severe osteoarthritis of the knee. BIOF2 can regenerate articular cartilage and is an easily implemented alternative therapy for the treatment of osteoarthritis. Trial registration Cuban Public Registry of Clinical Trials (RPCEC) Database RPCEC00000250. Registered 08/15/2017— Retrospectively registered, http://rpcec .sld.cu/en/trial s/RPCEC 00000 250‑En. 2018 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/15983/1/56.pdf http://eprints.uanl.mx/15983/1.haspreviewThumbnailVersion/56.pdf Delgado Enciso, Iván y Paz Garcia, Juan y Valtierra Alvarez, Jose y Preciado Ramirez, Jorge y Almeida Trinidad, Román y Guzman Esquivel, José y Mendoza Hernandez, Martha A. y García vega, Alberto y Soriano Hernandez, Alejandro D. y Cortes Bazan, José L. y Galvan Salazar, Héctor R. y Cabrera Lincona, Ariana y Rodríguez Sánchez, Irám Pablo y Martínez Fierro, Margarita de la Luz y Delgado Enciso, Josuel y Paz Michel, Brenda (2018) A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee. European Journal of Medical Research, 23 (1). pp. 1-11. ISSN 2047-783X http://doi.org/10.1186/s40001-018-0349-2 doi:10.1186/s40001-018-0349-2
spellingShingle QR Microbiología
Delgado Enciso, Iván
Paz Garcia, Juan
Valtierra Alvarez, Jose
Preciado Ramirez, Jorge
Almeida Trinidad, Román
Guzman Esquivel, José
Mendoza Hernandez, Martha A.
García vega, Alberto
Soriano Hernandez, Alejandro D.
Cortes Bazan, José L.
Galvan Salazar, Héctor R.
Cabrera Lincona, Ariana
Rodríguez Sánchez, Irám Pablo
Martínez Fierro, Margarita de la Luz
Delgado Enciso, Josuel
Paz Michel, Brenda
A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee
thumbnail https://rediab.uanl.mx/themes/sandal5/images/online.png
title A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee
title_full A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee
title_fullStr A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee
title_full_unstemmed A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee
title_short A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee
title_sort phase i ii controlled randomized trial using a promising novel cell free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee
topic QR Microbiología
url http://eprints.uanl.mx/15983/1/56.pdf
work_keys_str_mv AT delgadoencisoivan aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT pazgarciajuan aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT valtierraalvarezjose aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT preciadoramirezjorge aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT almeidatrinidadroman aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT guzmanesquiveljose aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT mendozahernandezmarthaa aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT garciavegaalberto aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT sorianohernandezalejandrod aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT cortesbazanjosel aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT galvansalazarhectorr aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT cabreralinconaariana aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT rodriguezsanchezirampablo aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT martinezfierromargaritadelaluz aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT delgadoencisojosuel aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT pazmichelbrenda aphaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT delgadoencisoivan phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT pazgarciajuan phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT valtierraalvarezjose phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT preciadoramirezjorge phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT almeidatrinidadroman phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT guzmanesquiveljose phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT mendozahernandezmarthaa phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT garciavegaalberto phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT sorianohernandezalejandrod phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT cortesbazanjosel phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT galvansalazarhectorr phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT cabreralinconaariana phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT rodriguezsanchezirampablo phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT martinezfierromargaritadelaluz phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT delgadoencisojosuel phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee
AT pazmichelbrenda phaseiiicontrolledrandomizedtrialusingapromisingnovelcellfreeformulationforarticularcartilageregenerationastreatmentofsevereosteoarthritisoftheknee